1-4 of 4
Yuval Shaked
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab

Angelica Calleri, Anna Bono, Vincenzo Bagnardi, Jessica Quarna, Patrizia Mancuso, Cristina Rabascio, Silvia Dellapasqua, Elisabetta Campagnoli, Yuval Shaked, Aron Goldhirsch, Marco Colleoni, Francesco Bertolini
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (24): 7652–7657.
https://doi.org/10.1158/1078-0432.CCR-09-1493
Published: 14 December 2009
View article titled, Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
Open the PDF for Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab in another window
Journal Articles

Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth

Fernando Doñate, Graham C. Parry, Yuval Shaked, Harvey Hensley, Xiaojun Guan, Ivy Beck, Ziva Tel-Tsur, Marian L. Plunkett, Mari Manuia, David E. Shaw, Robert S. Kerbel, Andrew P. Mazar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (7): 2137–2144.
https://doi.org/10.1158/1078-0432.CCR-07-4530
Published: 01 April 2008
View article titled, Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH<sub>2</sub>): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth
Open the PDF for Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH<sub>2</sub>): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth in another window
Journal Articles

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

Rena Buckstein, Robert S. Kerbel, Yuval Shaked, Rakesh Nayar, Cindy Foden, Ruth Turner, Christine R. Lee, Diane Taylor, Liying Zhang, Shan Man, Sylvain Baruchel, Diana Stempak, Francesco Bertolini, Michael Crump
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5190–5198.
https://doi.org/10.1158/1078-0432.CCR-06-0474
Published: 01 September 2006
View article titled, High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
Open the PDF for High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma in another window
Journal Articles

Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel

Sylvia S.W. Ng, Alex Sparreboom, Yuval Shaked, Christina Lee, Shan Man, Neil Desai, Patrick Soon-Shiong, William D. Figg, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4331–4338.
https://doi.org/10.1158/1078-0432.CCR-05-2762
Published: 20 July 2006
View article titled, Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel
Open the PDF for Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel in another window